Investor Hub
Latest quarterly earnings
Latest investor presentation
Latest clinical presentation
Annual report
Latest publications
Pipeline
NASDAQ:NVAX
NASDAQ:NVAX
Latest quarterly earnings
Latest investor presentation
Latest clinical presentation
Annual report
Latest publications
Pipeline
Latest press releasesEvents & presentationsReports & financialsSEC filingsStock details & analyst coverage
Press releases & statements
Jun 11, 2025
COVID-19,Seasonal influenza
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
May 29, 2025
Corporate and finance
Novavax to Participate in Upcoming Investor Conferences
Latest press releasesEvents & presentationsReports & financialsSEC filingsStock details & analyst coverage
Press releases & statements
Jun 11, 2025
COVID-19,Seasonal influenza
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
May 29, 2025
Corporate and finance
Novavax to Participate in Upcoming Investor Conferences
Get notifications for investor updates
Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings and more.
Shareholders seeking information can contact investor relations at (240) 268-2022 or contact us.
Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.
